Manganese Ions Chelated Melanin Ultra-Small Nanostructure for PET/MR Bimodal Imaging-Guided Acute Kidney Injury Therapy

Tuanwei Sun,Dawei Jiang,Emily Ehlerding,Zachary Rosenkrans,Dalong Ni,Carolina Ferreira,Jonathan Engle,Weibo Cai
2019-01-01
Journal of Nuclear Medicine
Abstract:413 Objectives: Melanin, a naturally occurring biopolymer, has many fascinating characteristics such as good biocompatibility and biodegradability, strong chelating capability to metal ions, and excellent antioxidant activities. Thus, melanin is attracting intense attention for molecular imaging and treating of reactive oxygen species (ROS)-related diseases. Acute kidney injury (AKI), a common ROS-related renal disease, is in urgent need of effective treatment. Nanomedicine shows great potential in targeted drug delivery, but it still faces the huge challenge of controlling the accumulation of nanoparticles in kidney. Our goal is to develop a melanin ultra-small nanostructure for good renal accumulation and AKI therapy in mice. Methods: Manganese (Mn) ions chelated melanin ultra-small nanoparticles (MMP) were prepared via a one-pot micelle formation technique and further treated with PEGylation (MMPP). Because of the intrinsic chelating function of melanin, radionuclide Zr-89 (half-life: 78.4 h) labeled MMPP (89Zr-MMPP) was obtained by chelator-free labeling. Positron emission tomography (PET) imaging of 89Zr-MMPP and magnetic resonance (MR) imaging of MMPP were performed to evaluate the biodistribution in AKI mice. The AKI model was induced by intramuscular injection of 50% glycerol into both hind limbs of mice (8 mL/kg). MMPP was intravenously injected for AKI therapy with different doses. The therapeutic effect of MMPP was determined by measuring serum creatinine and blood urea nitrogen concentrations as well as kidney tissue staining. Results: The MMP and MMPP are ultra-small nanodots with sizes of 3.4 nm and 4.5 nm, respectively. The r1 value of MMPP was calculated to be 46.5 mM−1 s−1 at 4.7 T, which is a comparatively high value among reported relaxivities of nanosized Mn-based MR contrast agents and is about 7.5 times larger than that of gadobenate dimeglumine (Gd-BOPTA, a gadolinium-based contrast agent). The MR imaging revealed the enhanced T1-weighted MR signal within the kidneys of AKI mice after intravenous injection of MMPP. PET imaging also showed good accumulation of MMPP in the kidneys of AKI mice (13.8 ± 1.7 %ID/g at 10 min post-injection and 4.8 ± 0.4 %ID/g at 24 h post-injection; n=3). In addition, MMPP showed almost no toxicity to the major organs of healthy mice even at a high dose (1 mg of melanin per mouse). Furthermore, MMPP was found to alleviate AKI at the dose of 200 µg melanin per mouse and therapeutically effective at the dose of 500 µg melanin per mouse, which was confirmed by serum tests and kidney tissue staining. Conclusion: Based on the PET and MR bimodal imaging, MMPP showed a good renal accumulation in AKI mice, which enable MMPP to treat AKI induced by 50% glycerol in vivo. Moreover, MMPP may serve as a renal protective material to prevent or treat other ROS-related kidney diseases.
What problem does this paper attempt to address?